Assessment of Immunotherapy Response by Analyzing Tumor Microenvironment Alterations in Advanced Gastric Cancer: A Study Protocol
Open Access
- 1 September 2026
- journal article
- Published by SAGE Publications in Cancer Control
- Vol. 33
Abstract
Introduction: Advanced gastric cancer has a poor prognosis, and reliable biomarkers for identifying patients who may benefit from immune checkpoint inhibitors (ICIs) combined with chemotherapy remain limited. Dynamic alterations in the tumor microenvironment (TME) may provide clinically useful information regarding treatment response. This study aims to investigate longitudinal TME changes in patients with advanced gastric cancer receiving ICIs plus chemotherapy and to explore their associations with treatment response. Methods: This is a prospective, single-center biomarker study in patients with advanced gastric cancer receiving ICIs plus chemotherapy. Matched tumor tissue samples from primary and/or metastatic lesions, together with peripheral blood samples, will be collected before treatment and after four cycles of combination therapy. Patients achieving complete response (CR) or partial response (PR) will be classified as the high-response group (HRG), whereas patients with progressive disease (PD) will be classified as the non-response group (NRG). Pre- and post-treatment TME alterations will be analyzed within each patient, and differences between the HRG and NRG will be compared, including tumor-infiltrating lymphocytes (TILs), H3K4me3, cytokines, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and tumor markers. Associations with programmed death-ligand 1 (PD-L1), mismatch repair (MMR), and Epstein–Barr virus-encoded RNA (EBER) status will also be explored. Conclusions: This study may identify dynamic TME-related biomarkers associated with response to ICIs combined with chemotherapy, and may provide evidence for future response-stratification strategies in advanced gastric cancer.Funding Information
- the Basic Research Program of Shanxi Province (202303021212365)
- The CAPTRA-STAR Research Grant Project of the Beijing Cancer Prevention and Treatment Research Association (KY202501031)
This publication has 42 references indexed in Scilit:
- First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric CancerJAMA, 2025
- Roles of H3K4 methylation in biology and diseaseTrends in Cell Biology, 2024
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancerESMO Open, 2024
- Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction CancerJAMA, 2023
- Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trialThe Lancet Oncology, 2022
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trialThe Lancet, 2021
- Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical TrialsJAMA Oncology, 2021
- Clinicopathological and prognostic features of Epstein‐Barr virus infection, microsatellite instability, and PD‐L1 expression in gastric cancerJournal of Surgical Oncology, 2018
- Determinants of Histone H3K4 Methylation PatternsMolecular Cell, 2017
- Classification of Advanced Human Cancers Based on Tumor Immunity in the MicroEnvironment (TIME) for Cancer ImmunotherapyJAMA Oncology, 2016